Reading time:3 minutes, 24 seconds
If you are looking for information on the Diabetic Macular Edema market, this report provides the whole scope regarding its market size and number of business opportunities offered. In addition, key industry players helping to create a competitive edge and the technological advancements utilized in this market are also profiled.
Click on the tab below to benefit from the sample copy of the report
What is Diabetic Macular Edema?
Diabetic macular edema is a condition that occurs when fluid builds up in the back of the eye and causes vision loss. It often affects people with diabetes. Diabetic macular edema (DME) is a disease of the retina that results in inflammation of the macula, which is a small area in the center of the retina. High blood sugar is the cause in people with diabetes, which can damage the blood vessels in their eyes. DME can lead to severe visual impairment and blindness, so blood sugar monitoring and control is essential.
Market growth and future prospects
The DMED market is expected to grow at a CAGR of 18.1% from 2018 to 2027, driven by the increasing prevalence of DMED in the elderly, who are more vulnerable to developing this disease. Moreover, the increased prevalence of diabetes and obesity also bodes well for the growth of this market.
Benefits of technology
Diabetic macular edema is the leading cause of visual impairment in people with diabetes. In patients, the disease results in an accumulation of fluid under the retina, resulting in permanent vision loss. Diabetic retinopathy is already one of the most common diseases in the world. As people live longer, more patients with diabetes will be at risk of developing the disease. Although there are many treatments available, diabetic macular edema has a high recurrence rate after treatment. Technology has had some success in treating this condition with lasers or light therapy that works on the blood vessels under the retina…
Market share by company
According to the report, by 2022-2027, the global market share is expected to be held by companies such as Abbott Laboratories and Novartis. Market share: –
– Market Growth:-
– Technological growth: –
– Professional opportunities: –
#4: EYLEA SA
EYLEA SA, headquartered in Madrid, Spain, is a medical device company engaged in the development and sale of treatments for patients with diabetic macular edema. Diabetic macular edema is characterized by abnormal leakage of fluid from blood vessels in the retina. It can cause severe vision loss and lead to blindness if left untreated.
Diabetic macular edema (DME) is a condition that damages the central part of the retina, which can lead to permanent visual impairment. High blood glucose levels cause DMO, and diabetes is one of the main causes. Therefore, the market for this condition is expected to grow as more people develop diabetes, and research continues.
Main companies in the sector
The global diabetic macular edema market is expected to reach USD 1.29 billion by 2027 driven by lens sales. The main companies in this sector are Bausch & Lomb (USA), Alcon (Switzerland) and CooperVision (USA). Key players in the diabetic macular edema treatments market include Abbott Laboratories, Bausch + Lomb, Genentech Inc., Merck & Co., Inc., and Novartis AG.
Click on the tab below for the instant purchase of the report with a flat rate discount of $500
Instant Buy Request
The current diabetic macular edema market size is valued at US$1,857 million in 2017. It is expected to reach US$5,945 million by 2027, growing at a compound annual growth rate (CAGR) of 8. 2%. As a result, the global diabetic macular edema market is expected to reach USD 3.3 billion by the end of 2022 growing at a CAGR of 4.7% from 2017 to 2022. Factors such as the rising incidence of diabetes type 2 and the aging population are expected to drive demand for diabetic macular edema treatment. Additionally, the increasing prevalence of obesity and increasing incidence of cataract surgery are also likely to contribute to the growth of the global market.